-
Ra Pharmaceuticals (RARX) Announces $100 Million Proposed Public Offering of Common Stock
-
Ra Pharmaceuticals Announces Proposed Public Offering of Common Stock
-
Ra Pharma (RARX) PT Lowered to $33 at BMO Capital
-
Ra Pharmaceuticals (RARX) Prices 8.387M Share Common Offering at $15.50/Sh
-
Ra Pharmaceuticals Announces Pricing of Public Offering of Common Stock
-
Ra Pharmaceuticals (RARX) Announces Proposed $100M Public Offering of Common Stock
-
Ra Pharmaceuticals Announces Proposed Public Offering of Common Stock
-
Ra Pharma (RARX) PT Raised to $34 at BMO Capital
-
Ra Pharma (RARX) PT Raised to $21 at BMO Capital
-
BMO Capital Starts Ra Pharma (RARX) at Outperform
-
Ra Pharma (RARX) PT Lowered to $31 at BMO Capital; Sees Shares Range Bound Until Data in Q2
-
Ra Pharmaceuticals (RARX) Prices 8.4M Common Stock Offering at $6/Share
-
Ra Pharmaceuticals Announces Pricing of Public Offering of Common Stock
-
Ra Pharmaceuticals (RARX) to Offer $50M of Common Stock
-
Ra Pharmaceuticals Announces Proposed Public Offering of Common Stock
-
Ra Pharmaceuticals to Present at the BMO Capital Markets Prescriptions for Success Healthcare Conference
-
Ra Pharma (RARX) PT Raised to $34 at BMO Capital
-
Ra Pharma (RARX) PT Raised to $31 at BMO Capital on Positive RA101495 Expectations
-
Ra Pharmaceuticals to Present at the BMO Capital Markets Prescriptions for Success Healthcare Conference
-
BMO Capital Starts Ra Pharma (RARX) at Outperform
-
Ra Pharmaceuticals (RARX) Prices Larger Common Stock IPO at $13/Share, in Middle of Expected Range
-
Ra Pharmaceuticals Announces Pricing of Initial Public Offering

